Effective and durable repigmentation for stable vitiligo: a randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation

Iltefat H Hamzavi,Anand K Ganesan,Bassel H Mahmoud,Eduardo Weiss,Ammar M Ahmed,Deanne Robinson,Mitchel P Goldman,Girish Munavalli,Steven A Kahn,Victor Huang,Jill Waibel,Alpesh Desai,Nada Elbuluk,Seemal Desai,Amit G Pandya
DOI: https://doi.org/10.1016/j.jaad.2024.08.027
2024-08-23
Abstract:Background: Vitiligo lesions are often challenging to repigment with conventional medical therapies. Surgical autologous melanocyte transfer methods can be utilized for stable vitiligo but demand specialized skills and equipment. A point-of-care autologous cell harvesting device was designed enabling simple preparation of autologous skin cell suspension (ASCS) containing melanocytes, keratinocytes, and fibroblasts providing a straightforward approach for cellular transplantation. Objective: To evaluate the safety and effectiveness of ASCS for repigmentation of stable vitiligo lesions among adults. Methods: A US multicenter, randomized, within-subject controlled trial compared ASCS to NB-UVB only (Control) in similar vitiligo lesions. ASCS was applied after laser skin resurfacing and followed by NB-UVB treatment. The primary effectiveness endpoint was the proportion of lesions achieving ≥80% repigmentation at week-24. Repigmentation durability was assessed at week-52. Results: Among 25 subjects, 36% of ASCS-treated lesions achieved ≥80% repigmentation at week-24 compared to 0% for Control (p<0.025), with durability through week-52. The safety profile of ASCS was acceptable, with favorable patient- and investigator-reported outcomes. Limitations: Study sample size limited robust subgroup analyses. Conclusion: Application of ASCS is a safe and effective treatment for repigmentation of stable vitiligo lesions with the potential to improve health-related quality of life and reduce burden of disease.
What problem does this paper attempt to address?